Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis by Forrest EH et al.
 
 
 
 
 
Newcastle University ePrints | eprint.ncl.ac.uk 
Forrest EH, Atkinson SR, Richardson P, Masson S, Ryder S, Thursz MR, Allison 
M. Application of prognostic scores in the STOPAH trial: Discriminant function 
is no longer the optimal scoring system in alcoholic hepatitis. Journal of 
Hepatology (2018)
DOI link 
https://doi.org/10.1016/j.jhep.2017.11.017  
ePrints link 
http://eprint.ncl.ac.uk/pub_details2.aspx?pub_id=245542  
Date deposited 
30/01/2018 
Embargo release date 
21/11/2018  
Copyright 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
 
Licence 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence 
 
 
Accepted Manuscript
Application of Prognostic Scores in The Stopah Trial: Discriminant Function is
no Longer the Optimal Scoring System in Alcoholic Hepatitis
Ewan H Forrest, Stephen R Atkinson, Paul Richardson, Steven Masson, Stephen
Ryder, Mark R Thursz, Michael Allison, On behalf of the STOPAH Trial
Management Group,
PII: S0168-8278(17)32440-6
DOI: https://doi.org/10.1016/j.jhep.2017.11.017
Reference: JHEPAT 6759
To appear in: Journal of Hepatology
Received Date: 27 February 2017
Revised Date: 21 October 2017
Accepted Date: 1 November 2017
Please cite this article as: Forrest, E.H., Atkinson, S.R., Richardson, P., Masson, S., Ryder, S., Thursz, M.R., Allison,
M., On behalf of the STOPAH Trial Management Group, Application of Prognostic Scores in The Stopah Trial:
Discriminant Function is no Longer the Optimal Scoring System in Alcoholic Hepatitis, Journal of Hepatology
(2017), doi: https://doi.org/10.1016/j.jhep.2017.11.017
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
Prognostic Scores in Alcoholic Hepatitis 
 
1 
 
APPLICATION OF PROGNOSTIC SCORES IN THE 
STOPAH TRIAL: DISCRIMINANT FUNCTION IS NO 
LONGER THE OPTIMAL SCORING SYSTEM IN 
ALCOHOLIC HEPATITIS 
 
Ewan H Forrest1, Stephen R Atkinson2, Paul Richardson3, Steven Masson4, Stephen 
Ryder5, Mark R Thursz2, Michael Allison6 
On behalf of the STOPAH Trial Management Group* 
 
1 Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow 
2 Liver Unit, Imperial College, London 
3 Liver Unit, Royal Liverpool Hospital, Liverpool 
4 Liver Unit, Freeman Hospital, Newcastle 
5 Liver Unit, Queen’s Medical Centre, Nottingham 
6 Liver Unit, Addenbrooke’s Hospital, Cambridge Biomedical Research Centre, Cambridge 
 
*Members of the STOPAH Trial Management Group other than the authors: Dr Anne McCune, Bristol; 
Dr Dermot Gleeson, Sheffield; Dr Andrew Austin, Derby; Dr David Patch, London, Dr Ashwin Dhanda, 
Plymouth; Dr Debbie Shawcross, London; Dr Mark Wright, Southampton. 
 
Correspondence to: 
Dr Ewan Forrest 
Department of Gastroenterology 
Glasgow Royal Infirmary 
Castle Street 
Glasgow G4 0SF 
United Kingdom 
 
Tel:  0141 232 0734 
Fax:  0141 552 6126 
E mail: Ewan.Forrest@ggc.scot.nhs.uk 
 
KEYWORDS: Alcoholic Hepatitis; Prednisolone; Prognosis 
 
Word Count: 5153; Figures: 2 Tables: 6; Supplementary Figures: 2; Supplementary Tables: 4 
Conflicts of Interest: none 
Financial Support: STOPAH Trial funded by the National Institute for Health Research Health 
Technology Assessment program. 
Author Contributions: Study Concept and Design: EHF, SRA, MA; Analysis and Interpretation of Data: 
EHF, SRA, MA; Drafting of Manuscript: EHF; SRA, MA; Critical Revision of Manuscript for Important 
Intellectual Content: EHF, SRA, PR, SM, MRT, MA. 
 
Acknowledgments: 
Dr Alan H Forrest, Fellow of Royal Statistical Society, and Dr Caroline E. Haig, Robertson Centre for 
Biostatistics, University of Glasgow for statistical advice.  
  
Prognostic Scores in Alcoholic Hepatitis 
 
2 
 
ABSTRACT 
Background and Aims: 
‘Static’ prognostic models in alcoholic hepatitis (AH), using data from a single time 
point, include the Discriminant Function (DF), Glasgow Alcoholic Hepatitis Score 
(GAHS), the Age, Bilirubin, INR and Creatinine (ABIC) score and the Model of End-
Stage Liver Disease (MELD).'Dynamic' scores, incorporating evolution of bilirubin at 
7 days, include the Lille Score. The aim of this study was to assess these scores’ 
performance in patients from the STOPAH trial. 
Methods: 
Predictive performance of scores was assessed by area under the Receiver 
Operating Curve (AUC). The effect of different therapeutic strategies upon survival 
was assessed by Kaplan-Meier analysis and tested using the log-rank test. 
Results: 
1068 patients were studied. The AUCs for the DF were significantly lower than for 
MELD, ABIC and GAHS for both 28- and 90-day outcomes: 90-day values 0.670, 
0.704, 0.726 and 0.713 respectively. ‘Dynamic’ scores and change in ‘static’ scores 
by Day 7 had similar AUCs. Patients with consistently low ‘static’ scores had low 28-
day mortalities not improved with prednisolone (MELD<25: 8.6%; ABIC<6.71: 6.6%; 
GAHS<9: 5.9%). In patients with high ‘static’ scores without gastro-intestinal 
bleeding or sepsis, prednisolone reduced 28-day mortality (MELD: 22.2% v 28.9%, 
p=0.13; ABIC 14.6% v 21% p=0.02 GAHS 21% v 29.3%, p=0.04). Overall mortality 
from treating all patients with a DF ≥ 32 and Lille assessment (90-day mortality 
26.8%) was greater than combining newer ‘static’ and ‘dynamic’ scores (90-day 
mortality: MELD/Lille 21.8%; ABIC/Lille 23.7%; GAHS/Lille 20.6%). 
Conclusion: 
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MELD, ABIC and GAHS are superior to the DF in alcoholic hepatitis. Consistently 
low scores have a favourable outcome not improved with prednisolone. Combined 
baseline ‘static’ and Day 7 scores reduce the number of patients exposed to 
corticosteroids and improve 90-day outcome. 
 
Lay Summary: 
Alcoholic hepatitis is a life-threatening condition. Several scores exist to determine 
the outcome of these patients as well as to identify those who may benefit from 
treatment. This study looked at the performance of existing scores in patients who 
had been recruited to the largest alcoholic hepatitis clinical trial: STOPAH. 
‘Static’ scores are calculable at the start of assessment. The three newer static 
scores (ABIC, GAHS and MELD) were shown to be superior to the oldest score 
(DF). ABIC and GAHS could also identify patients who had a survival benefit 28 days 
after starting prednisolone treatment. ‘Dynamic’ scores relate to the change in 
disease over the first week of treatment. Combination of the ‘static’ scores ‘with the 
‘dynamic’ scores or change in ‘static’ scores allowed identification of patients who 
could benefit from prednisolone up to 90 days. 
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INTRODUCTION 
Alcoholic hepatitis is an acute and florid manifestation of alcoholic liver disease with 
high short and medium-term mortality1. Recognition of those at risk of a poor 
outcome is fundamental to structuring patient management. Several prognostic 
scores have been developed to predict the course of alcoholic hepatitis, however to 
be useful in a clinical context, scores should not only identify patients with a poor 
prognosis but also direct patient care2. 
The Discriminant Function (DF) has become established in clinical practice with a 
threshold greater than or equal to 32 identifying those with severe disease3,4. 
However concerns have been raised regarding the reliability of the DF as it uses the 
absolute value of prothrombin time rather than a ratiometric value such as the 
International Normalised Ratio (INR)5. Combined analysis of five alcoholic hepatitis 
trials which used the DF to determine severity showed 28-day mortality of 20% for 
corticosteroid treated patients and 35% for untreated patients6. However, several of 
these studies were more than twenty years old3,7,8. More recent studies including the 
Steroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial have shown 
improvements in 28-day outcome9,10,11. These improved outcomes with the modern 
management of alcoholic hepatitis will likely reduce further the specificity of the DF to 
identify those at greatest risk of death compared with historical trials. 
Three alternative scores have been proposed to determine prognosis based upon 
variables obtained from a single time-point described as ‘static’ scores. These are 
the Glasgow Alcoholic Hepatitis Score (GAHS)1, the Age, Bilirubin, INR and 
Creatinine (ABIC) score12 and the Model of End-Stage Liver Disease (MELD) score. 
These scores seek to stratify patients into two (GAHS, MELD) or three (ABIC) 
groups characterised by significantly different prognoses. Well established cut-offs 
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exist for the GAHS (severe disease: >8) and ABIC (low, intermediate, high:) scores. 
There is no widely accepted optimal cut off for MELD; proposed values range from 
18 to 30.513,14,15,16. The ABIC score seeks to stratify patients into those at low, 
intermediate or high risk of death with those in the intermediate group perhaps most 
likely to benefit from corticosteroids. In a retrospective study the GAHS has been 
suggested as being able to identify those who are likely to benefit from corticosteroid 
treatment17. 
‘Dynamic’ scores which include the change in bilirubin levels over the first week of 
treatment have been used to assess likely benefit from corticosteroid therapy. These 
are the Early Change in Bilirubin Levels (ECBL)18, percentage change in serum 
bilirubin (%∆Bili)19 and the Lille Score20. These scores were originally described to 
be used in a dichotomous fashion with any fall in bilirubin (ECBL), a greater than or 
equal to 25%∆Bili or a Lille Score less than 0.45 being associated with a favourable 
outcome, or corticosteroid 'response'. Patients admitted with alcoholic hepatitis 
present at different stages of their illness. Whilst some will present at a point where 
their disease severity is at its worst and then improve; others will present at a point 
where their disease is on a continuing trajectory of deterioration. Given this variation 
it is not unexpected that baseline severity scores, although they can give an index of 
severity and mortality risk, may have relatively low predictive value. By the same 
logic, it would be anticipated that a means of assessment of the severity that 
incorporates the evolution of disease over time, with or without treatment, would be 
more accurate in predicting outcome. The combination of a ‘static’ score with a 
‘dynamic’ score would seem to be a reasonable strategy to identify those with an 
initial poor prognosis whose condition does not show improvement after starting 
corticosteroid treatment21. 
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The aim of this study was to assess the performance of these existing scores for 
alcoholic hepatitis to predict outcome and to assess their application to different 
treatment strategies in patients recruited to the STOPAH trial. 
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METHODS 
Patients recruited to the STOPAH trial were studied. The characteristics of these 
patients have been described in detail previously22. Inclusion was based upon a 
clinical diagnosis of alcoholic hepatitis with recent onset of jaundice and heavy 
alcohol misuse and no other forms of liver disease. All patients had a baseline DF 
greater than or equal to 32. Patients were randomised by a factorial design to 
receive Prednisolone and Placebo, Pentoxifylline and Placebo, Prednisolone and 
Pentoxifylline or double Placebo. Analysis was performed on an intention to treat 
basis. 
‘Static’ scores (GAHS, ABIC and MELD) were calculated on baseline data at the 
time of starting treatment: ‘dynamic’ scores (Lille, ECBL and %∆Bili) were calculated 
only in those patients with data available after 7 days of treatment. In addition the 
changes (Delta, ∆) of each of the ‘static’ scores between baseline and Day 7 were 
calculated. As the GAHS is a categorical score allocating a natural number to each 
variable to create a score, it was possible to categorise some patients as greater 
than or less than 9 even if some variables were missing if categorisation was 
arithmetically inevitable. The MELD was calculated using the UNOS variation. A high 
ABIC score was defined as a value greater than or equal to 6.71. 
Assessment of Prognosis 
For the purposes of assessing the overall discriminatory ability of static scores and 
comparison between them, the whole patient cohort was studied. Mortality at 28 and 
90 days after randomisation were analysed. Survival beyond 90 days was not 
assessed in this context as other factors, such as continued alcohol use, were felt to 
influence outcome beyond that point and so not be reflective of a prognostic score’s 
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accuracy. Patients were consented for follow-up using the NHS data linkage service 
so that even if lost to follow-up their outcomes could be captured. 
Application to Treatment Strategies 
The application of these scores to different treatment strategies which integrated 
‘static’ and ‘dynamic’ was assessed. The overall STOPAH results showed no 
therapeutic effect with pentoxifylline at any time point and so patients randomised to 
pentoxifylline were analysed as per untreated (placebo) patients. Thus the 
therapeutic comparison was for those treated with prednisolone or not. Whilst 
assessing the whole patient cohort, two pre-specified analyses were included. 
Initially all patients treated with prednisolone were analysed and then those who 
presented with either gastrointestinal bleeding (GIB) or sepsis were excluded for 
further analysis. Secondly patients with low MELD, GAHS or ABIC scores at 
baseline for whom no further score was available at seven days or whose Day 7 
score remained favourable were analysed separately to represent those with 
consistently low scores. 
The treatment strategies were based upon only treating patients with high initial 
baseline ‘static’ scores (MELD≥25; ABIC≥6.71 or GAHS>8) and assessing response 
at Day 7 by either change in ‘static’ score or by ‘dynamic’ scores. 
Analyses were performed using MedCalc Statistical Software version 17.6 (MedCalc 
Software bvba, Ostend, Belgium; http://www.medcalc.org; 2017) and R version 3.4.1 
(R Foundation for Statistical Computing, Vienna, Austria; https://www.R-project.org/). 
Comparison of scores was performed by area under the Receiver Operating Curve 
(AUC) analysis and Harrell’s c-statistic. Optimal cut-offs were identified by 
calculating the Youden Index (J). Kaplan-Meier analysis was used to assess survival 
and survival curves were compared using the Log-Rank test. Results are presented 
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with 95% confidence intervals (95% CI). Number needed to treat calculations were 
made using the inverse of the absolute risk reduction. 
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RESULTS 
Data on 1068 patients recruited to the STOPAH trial was available for analysis: of 
whom 534 received prednisolone. Patient characteristics are shown in Table 1. GIB 
and/or sepsis were features of initial presentation in 199 patients leaving 869 
patients who presented without either of these complications. At Day 7 data was 
available on 720 patients to calculate the dynamic scores indicating corticosteroid 
effect: GIB or sepsis were presenting features of 143 patients who had Day 7 data 
available, leaving 577 who presented without either of these complications 
(Supplementary Figure 1). 
Assessment of Prognosis 
Mortality data up to and including Day 90 were available for all patients. Overall 
mortality was 16.3% and 26.7% at 28 and 90 days respectively. For those presenting 
with GIB or sepsis initially the mortalities were 18.1% and 29.2% compared with 
15.9% and 26.1% for those without these features. 
Analysis of Baseline ‘Static’ Scores 
The AUC and Harrell’s c-statistic analyses are shown in Figure 1. For prediction of 
both 28-day and 90-day outcomes the MELD, ABIC and GAHS had similar values 
without any significant differences. For 28-day outcome the AUC values were 0.732, 
0.747 and 0.753, and for 90-day outcome 0.704, 0.726 and 0.713 respectively. 
However all three of these ‘static’ scores were superior to the DF at both time-points 
(Table 2) which had AUC values of 0.673 and 0.670 for 28-day and 90-day outcome 
respectively. Although numerically lower, the c-statistic values for the ‘static’ scores 
showed a similar pattern. 
Calibration of ‘Static’ Scores 
  
Prognostic Scores in Alcoholic Hepatitis 
 
11 
 
For the ABIC and GAHS scores there are established cut-offs to identify prognostic 
groups. The MELD cut-off used to determine prognosis varies between publications. 
A recommended cut-off of 18 encompassed 99% of the STOPAH patients with a DF 
greater than or equal to 32 and was therefore thought to lack adequate specificity. 
The optimal cut-off using the STOPAH data was 25 (J=0.36 for 28-day and J=0.32 
for 90-day outcomes) This gave high negative predictive values of 91.4% and 83.2% 
for 28-day and 90-day outcomes respectively. The positive predictive values were 
more modest at 29.2% for 28-day outcome but improved to 43.2% for 90-day 
outcome. Comparison with the established cut-offs for the GAHS and ABIC scores 
are shown in Supplementary Table 1. 
Of the patients studied, 61% had a MELD less than 25, 14% had an ABIC less than 
6.71 and 53% had a GAHS less than 9 at baseline. Overall accuracy in identifying 
outcome at Day 28 was 66% for MELD greater than or equal to 25, 30% for ABIC 
greater than or equal to 6.71 and 61% for GAHS greater than or equal to 9. 
Day 7 Scores: Analysis of Evolution of ‘Static’ Scores and ‘Dynamic’ Scores 
Comparison of the change in ‘static’ score by Day 7 with the ‘dynamic’ scores 
indicated the Lille Score to have the highest AUCs of 0.732 and 0.722 and Hazard 
Ratios of 11.13 and 8.15 for 28- and 90-day outcomes respectively. The AUC values 
obtained for either the ‘dynamic’ scores or the changes in ‘static’ scores were not 
significantly different. However the c-statistic values for the change in ‘static scores 
increased when adjusted for their baseline scores. These scores, as well as with the 
initial baseline ‘static’ scores for those patients with Day 7 data available, are shown 
in Table 3. 
Some patients with an initial low baseline score showed an increase to a higher 
score category by Day 7. Of patients with an initial GAHS less than 9, 11.8% 
  
Prognostic Scores in Alcoholic Hepatitis 
 
12 
 
developed a GAHS greater than or equal to 9 on Day 7. For patients with an initial 
MELD less than 25, 4.5% subsequently developed a score greater than 25 and 2.6% 
of patients with an ABIC less than 6.71 showed a rise to greater than 6.7 by Day 7. 
Lille Score stratification of corticosteroid treated patients into three categories of 
complete, partial or null responders showed 28-day mortalities for each group of 
6.3%, 4.6% and 27.4%, and the 90-day mortalities 12.6%, 17.2% and 46.4% 
respectively. Mortalities at Day 28 and Day 90 using the original cut point of greater 
than or equal to 0.45 were 27.8% and 43.6%, with non-responders by this definition 
not significantly different from the null responders. 
Application to Treatment Strategies 
Outcome of Patients with Low Baseline ‘Static’ Scores (Supplementary Table 2) 
The mortality rates after 28 days for those with low initial ‘static’ scores not treated 
with prednisolone were 11.7%, 6.3% and 9.3% for low MELD, ABIC and GAHS 
values respectively. The equivalent mortality figures for those treated with 
prednisolone were 6.3%, 1.4% and 4.4%. The differences were significant for the 
MELD and GAHS values. However, any difference was not sustained to Day 90. 
Of this group of patients, those whose scores remained consistently below these 
thresholds had 28-day mortality rates that did not differ between those treated and 
not treated with prednisolone: treated 5.7%, 1.4% and 3.3% for low MELD, ABIC and 
GAHS values respectively; untreated 8.6%, 6.6% and 5.9%. Similarly there were no 
differences in 90-day mortality in this sub-group between steroid-treated and 
untreated patients. 
Those patients whose initial ‘static’ score was low, but then rose above these 
thresholds over 7 days had a poor outcome. For those whose GAHS rose to greater 
than or equal to 9, the 28-day and 90-day mortalities were 27.0% and 41.7% 
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respectively. A rise in MELD above 25 gave 28-day and 90-day mortalities were 
52.2% and 60.9% respectively. 
Outcome of Patients with High Baseline ‘Static’ Scores (Table 4) 
Analysis of all patients with high initial baseline scores did not show any survival 
benefit with prednisolone at either 28 or 90 days. However with the exclusion of 
those who present with either GIB or sepsis the 28-day mortality of patients with an 
initial ABIC score greater than 6.7 treated with prednisolone was 14.6% compared to 
21.0% for untreated patients (p=0.02; 95%CI 1.06, 2.13). Similarly for patients with a 
GAHS greater than 8 the 28-day mortality was 21.0% with prednisolone and 29.3% 
for those untreated (p=0.04; 95%CI 1.02, 2.24). Patients with a MELD greater than 
25 did not show a significant reduction in mortality at Day 28 with prednisolone 
treatment even with exclusion of GIB or septic patients. By Day 90 any difference in 
mortality between treated and untreated patients identified by any score had 
disappeared. The number needed to treat with prednisolone to prevent an individual 
death at 28 days was 19 for patients with a DF greater than or equal to 32, 16 for a 
MELD greater than or equal to 25, 12 for a GAHS greater than 8, and 16 for an ABIC 
greater than 6.7. 
‘Dynamic’ Scores and Evolution of ‘Static’ Scores in Prednisolone Treated Patients. 
‘Dynamic’ scores and evolution of ‘static’ scores were studied in patients who did not 
present with GIB or sepsis and who had high baseline ’static’ score categories. For 
evolution of ‘static’ scores, Youden Index analysis identified a fall in ABIC by greater 
than or equal to 0.29, GAHS by greater than or equal 1 or MELD by greater than or 
equal 2.6 to be indicative of a favourable outcome with prednisolone treatment. On 
comparison with untreated patients, prednisolone treatment led to a greater 
percentage fall in serum bilirubin by Day 7. The proportions of patients with high 
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baseline ‘static’ scores who could be classified favourably after 7 days by either 
‘dynamic’ scores or evolution of ‘static’ scores were greater for those patients who 
were treated with prednisolone (Table 5). 
Combination of Static and Dynamic Scores 
Assessment of different combinations of baseline ‘static’ scores, with a ‘dynamic’ 
scores or a change in ‘static’ scores over 7 days demonstrated differences between 
different therapeutic strategies. Combining a baseline (‘static’) score with a Day 7 
score (‘dynamic’ score or change in initial ‘static’ score over 7 days) allows 
separation of patients into three main groups: 1) a consistently low ‘static’ score; 2) a 
high initial ‘static’ score treated with corticosteroids with a favourable Day-7 
response; 3) a high initial ‘static’ score treated with corticosteroids with an 
unfavourable Day 7 response (Supplementary Figure 2). Compared with the 
standard approach of treating all patients with a DF greater than 32 with subsequent 
Lille assessment, such strategies led to fewer patients being exposed to 
prednisolone with a trend to an overall improvement in 90-day survival (Table 6). 
Only the GAHS/∆GAHS strategy led to a significant reduction in overall 90-day 
mortality (19.2% compared with 28.2%: p=0.026: 95%CI 0.63% to 14.72%). Survival 
curves for the DF/ Lille, MELD/ Lille, ABIC/ Lille, GAHS/Lille and GAHS/∆GAHS 
strategies are shown (Figure 2). 
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DISCUSSION 
Prognostic scores should be clinically useful as well as statistically sound. The DF 
has provided a consistency to clinical treatment and research in alcoholic hepatitis. 
However it is a sensitive score with less impressive specificity and alternative scores 
have been proposed: ‘static’ scores based on variables at a single timepoint such as 
MELD, ABIC and GAHS1,12,13 and ‘dynamic’ scores based upon evolution of serum 
bilirubin over the first week of corticosteroid treatment such as ECBL, %∆Bili and the 
Lille Score18,19,20. 
This analysis of STOPAH trial data shows that all three new ‘static’ scores performed 
similarly in predicting outcome at 28 and 90 days and with greater discriminatory 
power than the DF in this population all of whom had a DF greater than or equal to 
32. Therefore a re-calibration to a higher cut off of DF to make it more specific would 
still fall short of the newer scores' discriminatory ability. The analysis also indicates 
that a MELD threshold of 25 was optimal as previously described15. Analysis of the 
‘dynamic’ scores indicates that the Lille score has the highest Hazard Ratio for 
prognostic prediction, although the other dynamic scores and the 7-day change in 
‘static’ scores also perform well. Sub-stratification of the Lille into Complete, Partial 
and Null Responders did not appear to add any additional useful prognostic 
information compared with the original description of a 0.45 cut off6. Overall the 
newer scores are more useful than the DF but still have relatively modest 
discriminatory power. 
Whilst the three newer ‘static’ scores had similar prognostic capabilities, there were 
differences in the application of these scores and identification of patients who might 
benefit from corticosteroid treatment. An overall treatment benefit from prednisolone 
was seen in patients with low ‘static’ scores at baseline. However, the conduct of the 
  
Prognostic Scores in Alcoholic Hepatitis 
 
16 
 
STOPAH trial in this regard would not reflect clinical stratification based upon a 
second risk threshold. Sub-group analysis of patients with consistently low scores is 
justified by the dynamic nature of alcoholic hepatitis, with patients presenting at 
different stages of their illness. On account of this and the high sensitivity of the DF, 
patients with low values of newer more specific scores may move to higher values as 
their condition evolves in the absence of effective treatment. In clinical practice the 
movement of these patients to a poor prognostic group would trigger consideration of 
prednisolone treatment. 
In this retrospective sub-group analysis, patients with consistently low ‘static’ scores 
which did not rise above their threshold for severe disease had a favourable 
outcome irrespective of whether they received prednisolone or not, with no 
statistically significant additional benefit from prednisolone treatment. However 
despite having consistently low scores these patients still need optimal general 
clinical management including nutritional support and the surveillance and treatment 
of infection as indicated. They also require monitoring as an increase in the values of 
these scores above their threshold of severity is associated with a high mortality. In 
such circumstances corticosteroid treatment may be considered, essentially using 
the cut-off threshold of the ‘static’ prognostic score as a trigger to intervention. 
Patients with high baseline ‘static’ scores initially did not appear to benefit from 
prednisolone treatment. However on excluding those patients who presented initially 
with either GIB or sepsis an improvement in 28-day survival for those with high 
GAHS (greater than 8) and ABIC scores (greater than 6.70) was seen with 
prednisolone. There is evidence that the natural history of apparent alcoholic 
hepatitis in patients who present with these complications may be different. Patients 
presenting with GIB may have a more favourable outcome23 perhaps related to the 
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routine use of antibiotics in this clinical circumstance resulting in fewer infections10. 
Despite a previous study indicating that treated infection had no impact upon 
subsequent corticosteroid effect24, more recent data from the STOPAH trial indicates 
that those patients with sepsis at presentation do not benefit from corticosteroids 
unless combined with a continuing course of antibiotics25. Therefore patients with 
such complications at presentation should be considered as specific groups for 
whom corticosteroid monotherapy may not be suitable. 
Even with additional stratification using either the GAHS and ABIC scores, it was 
only possible to identify patients deriving short-term (28-day) benefit from 
prednisolone. However, when used in combination with a Day 7 score (a ‘dynamic’ 
score or change in ‘static’ score), it was possible to identify a sub-group of patients 
who derive benefit at 90 days. The benefit from prednisolone appeared to be related 
to a greater fall in bilirubin leading to more favourable Day 7 scores. 
The combination of these results indicates the scores can be applied clinically, such 
that consistently low ‘static’ scored patients do not receive prednisolone but high 
‘static’ score patients receive treatment with subsequent assessment at of response 
at Day 7. Compared to the standard approach of treating all patients with a DF 
greater than or equal to 32 and assessing by a Lille response at Day 7, use of the 
new scores would lead to fewer patients receiving prednisolone, more specific 
identification of corticosteroid non-responders and a reduction in overall mortality. 
This appeared to be particularly so using the GAHS as a baseline ‘static’ score and 
change in GAHS to assess response to treatment. 
Whilst these retrospective sub-group analyses reflect ‘real-world’ management of 
this group of patients, caution should be used in interpreting their results. The 
STOPAH trial was designed to prospectively evaluate the benefit derived from 
  
Prognostic Scores in Alcoholic Hepatitis 
 
18 
 
prednisolone treatment in patients with a DF greater than or equal to 32; 
consequently re-casting analyses based upon treatment instituted at a second, 
higher threshold of severity comes with an attendant risk of introducing bias. 
Nonetheless, it seems apparent that the use of a newer baseline score and a Day 7 
score to stratify treatment reduces exposure to prednisolone without detriment to 
patient outcome and merits prospective evaluation. 
In conclusion, application of existing prognostic scores to the largest prospective 
study of alcoholic hepatitis shows that the more recently advocated ‘static’ scores 
(ABIC, GAHS and MELD) are superior to the DF in determining mortality risk. 
Consistently low ‘static’ scores identify a sub-group with such a low event rate that 
any potential beneficial effect of prednisolone is difficult to establish. Prednisolone 
can be offered to those with high ‘static’ scores, excluding those who present initially 
with sepsis or GIB, with subsequent response assessed by a variety of measures 
after 7 days. The approach suggested in this paper reduces the number of patients 
exposed to corticosteroids, reserving this for those likely to derive benefit until Day 
90, and allows for identification of those with no response at Day 7 who should be 
considered for new interventional therapies. Whilst this approach can be used 
clinically, predictive abilities remain modest and there is a need for more accurate 
identification of patients who will respond to corticosteroid, ideally using information 
available at baseline, rather than at Day 7. 
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Figure and Table Legends 
 
Figure 1: AUC and c-Statistics for MELD, GAHS and ABIC Scores 
 
Figure 2: Kaplan-Meier Survival Probability for Patients Stratified by ‘Static’ Scores 
(only high baseline scores treated with prednisolone) combined with ‘Dynamic’ 
Scores (excluding initial presentation with GIB or sepsis). R: Responder; NR: Non-
responder 
A) DF/Lille; B) MELD/Lille; C) ABIC/ Lille; D) GAHS/Lille; E) GAHS/∆GAHS 
 
Table 1: Patient characteristics 
 
Table 2: Comparison of AUCs: MELD, ABIC and GAHS compared with DF for both 
28 and 90-day Outcome 
 
Table 3: Comparison of AUCs and c-Statistics: ‘Dynamic’ Scores (Lille, ECBL, 
%∆Bili), change in ‘static’ scores (∆MELD, ∆ABIC, ∆GAHS) and baseline ‘static’ 
scores (MELD, ABIC, GAHS: for patients with Day 7 data available only) for both 28 
and 90-day Outcome 
 
Table 4: A) Mortality in all Patients with High Static Scores; B) Mortality in Patients 
with High Static Scores (excluding patients presenting with GIB or Sepsis) 
 
Table 5: Effect of Prednisolone upon Day 7 bilirubin and Day 7 scores of Response. 
 
Table 6: Application of Scores to Different Therapeutic Strategies and 90-Day 
Mortality. 
 
Supplementary Figure 1: Flowchart of patients analysed. 
 
Supplementary Figure 2: Supplementary Figure 2: Flowchart showing Stratified 
Management of Patients with Alcoholic Hepatitis in the STOPAH Trial. 
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Supplementary Table 1: Comparison of Cut Offs for A) MELD, B) ABIC, C) GAHS, 
D) ECBL, E) %∆Bili, F) Lille Score 
 
Supplementary Table 2: A) Mortality in Patients with Low ‘Static’ Scores; B) Mortality 
in Patients with Consistently Low ‘Static’ Scores 
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Supplementary Figure 1: Flowchart of patients analysed. 
 
 
  
Alcoholic Hepatitis   (DF≥32)
n=1068
(534 Prednisolone Treated)
Exclusion of Primary GIB and Sepsis
n=869 (431 Prednisolone Treated)
Day 7 Data Available
n=577
(262 Prednisolone Treated)
Primary Presentation with GIB or Sepsis
n=199 (103 Prednisolone Treated)
Day 7 Data Available
n=143
(74 Prednisolone Treated)
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Table 1: Patient characteristics 
 
 Prednisolone Treated No Prednisolone 
Age 49.4 (48.5, 50.3) 48.8 (47.9, 49.6) 
Bilirubin (µmol/l) 308.3 (294.9, 321.7) 303.4 (290.6, 316.1) 
INR 1.86 (1.82, 1.90) 1.90 (1.86, 1.94) 
WCC (109/l) 10.1 (9.7, 10.6) 10.0 (9.5, 10.5) 
Creatinine (µmol/l) 81.6 (77.3, 85.9) 76.3 (72.4, 80.1) 
ABIC≥6.71 435 (86%) 435 (85%) 
ABIC≥9.0 141 (28%) 119 (23%) 
GAHS≥9 256 (48%) 250 (47%) 
MELD≥25 206 (40%) 199 (39%) 
Sepsis or GIB 103 (19%) 96 (18%) 
 
In parentheses: 95% Confidence Intervals or percentage of available data 
No significant differences between Prednisolone treated and untreated patients. 
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Figure 1: AUC and c-Statistics for MELD, GAHS and ABIC Scores 
 
 
 
 28-Day Outcome 90-Day Outcome 
 Hazard Ratio AUC c-Statistic Hazard Ratio AUC c-Statistic 
ABIC 1.95 
(1.75, 2.18) 
0.747 
(0.719, 0.774) 
0.734 
(0.689, 0.779) 
1.82 
(1.67, 1.99) 
0.726 
(0.697, 0.753) 
0.708 
(0.673, 0.743) 
DF 1.02 
(1.01, 1.02) 
0.673 
(0.643, 0.702) 
0.666 
(0.623, 0.709) 
1.01 
(1.01, 1.02) 
0.670 
(0.640, 0.699) 
0.658 
(0.625, 0.691) 
GAHS 1.96 
(1.73, 2.21) 
0.753 
(0.725, 0.779) 
0.729 
(0.686, 0.772) 
1.74 
(1.58, 1.91) 
0.713 
(0.684, 0.741) 
0.693 
(0.660, 0.726) 
MELD 1.17 
(1.14, 1.20) 
0.732 
(0.704, 0.759) 
0.723 
(0.678, 0.768) 
1.15 
(1.12, 1.17) 
0.704 
(0.675, 0.732) 
0.690 
(0.655, 0.725) 
95% Confidence Intervals in parentheses 
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Table 2: Comparison of AUCs: MELD, ABIC and GAHS compared with DF for both 
28 and 90-day Outcome 
 28-Day Outcome 90-Day Outcome 
ABIC ~ DF_   
95% Confidence Interval  0.020 to 0.128 0.009 to 0.103 
z statistic  2.673 2.333 
Significance level P = 0.008 P = 0.020 
DF ~ GAHS  
95% Confidence Interval  0.032 to 0.128 0.002 to 0.084 
z statistic  3.273 2.037 
Significance level P = 0.001 P = 0.042
DF ~ MELD  
95% Confidence Interval  0.026 to 0.093 0.006 to 0.062 
z statistic  3.453 2.352 
Significance level P = 0.001 P = 0.019 
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Supplementary Table 1: Comparison of Cut Offs for A) MELD, B) ABIC, C) GAHS, 
D) ECBL, E) %∆Bili, F) Lille Score 
A) MELD 
 Cut 
Off 
Sensitivity Specificity +PV 95% CI -PV 95% CI Accuracy 
28-Day 
Outcome 
≥25 66.06 69.19 29.2 24.7-34.1 91.4 88.9-93.4 65.5% 
90-Day 
Outcome 
≥25 59.63 71.81 43.2 38.1-48.4 83.2 80.1-86.0 66.2% 
B) ABIC 
 Cut 
Off 
Sensitivity Specificity +PV 95% CI -PV 95% CI Accuracy 
28-Day 
Outcome 
<6.70 96.36 17.11 18.3 15.7-21.0 96.1 91.7-98.5 29.8% 
≥9 52.73 79.86 33.5 27.8-39.6 89.8 87.4-91.8 73.2% 
90-Day 
Outcome 
<6.70 95.56 18.62 29.7 26.6-32.8 92.1 86.6-95.9 38.9% 
≥9 47.41 82.45 49.2 43.0-55.5 81.4 78.4-84.1 73.2% 
C) GAHS 
 Cut 
Off 
Sensitivity Specificity +PV 95% CI -PV 95% CI Accuracy 
28-Day 
Outcome 
≥9 77.51 58.00 26.1 22.4-30.2 93.1 90.6-95.1 61.2% 
90-Day 
Outcome 
≥9 70.61 60.57 39.3 35.0-43.8 85.1 81.8-87.9 63.2% 
D) ECBL 
 Cut 
Off 
Sensitivity Specificity +PV 95% CI -PV 95% CI Accuracy 
28 Day 
Outcome 
>0 47.06 83.84 30.2 18.3-44.3 91.4 86.8-94.8 70.1% 
90 Day 
Outcome 
>0 36.23 85.57 47.2 33.3-61.4 79.0 72.9-84.3 68.0%% 
E) %∆Bili 
 Cut 
Off 
Sensitivity Specificity +PV 95% CI -PV 95% CI Accuracy 
28 Day 
Outcome 
<25 79.41 56.58 21.4 14.6-29.6 94.9 89.7-97.9 49.6% 
90 Day 
Outcome 
<25 73.91 61.14 40.5 31.8-49.6 86.8 79.9-92.0 56.2% 
F) Lille Score 
 Cut 
Off 
Sensitivity Specificity +PV 95% CI -PV 95% CI Accuracy 
28 Day 
Outcome 
≥0.45 78.12 65.14 24.8 16.7-34.3 95.3 90.6-98.1 62.4% 
90 Day 
Outcome 
≥0.45 65.67 68.85 43.6 33.7-53.8 84.6 77.7-90.0 65.0% 
 
Accuracy indicates the percentage of correctly predicted outcomes using the cut offs 
described. 
+/-: positive/ negative; PV: Predictive Value 
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Table 3: Comparison of AUCs and c-Statistics: ‘Dynamic’ Scores (Lille, ECBL, 
%∆Bili), change in ‘static’ scores (∆MELD, ∆ABIC, ∆GAHS) and baseline ‘static’ 
scores (#MELD, ABIC, GAHS: for patients with day 7 data available only) for both 28 
and 90 day Outcome. 
 
 28-Day Outcome 90-Day Outcome 
 Hazard Ratio AUC c-Statistic Hazard Ratio AUC c-Statistic 
ECBL 1.01 
(1.00, 1.01) 
0.690 
(0.651, 0.727) 
0.683 
(0.630, 0.736) 
1.01 
(1.00, 1.01) 
0.668 
(0.629, 0.706) 
0.658 
(0.617, 0.699) 
%∆Bili 1.02 
(1.01, 1.02) 
0.703 
(0.664, 0.740) 
0.689 
(0.636, 0.742) 
1.02 
(1.01, 1.02) 
0.692 
(0.653, 0.730) 
0.673 
(0.632, 0.714) 
Lille 11.13 
(5.97, 20.76) 
0.732 
(0.694, 0.768) 
0.720 
(0.665, 0.775) 
8.15 
(5.15, 12.89) 
0.722 
(0.684, 0.758) 
0.698 
(0.657, 0.739) 
∆ABIC 2.58 
(1.36, 3.24) 
0.725 
(0.687, 0.761) 
0.756* 
(0.699, 0.813) 
2.32 
(1.91, 2.82) 
0.682 
(0.642, 0.719) 
0.735* 
(0.692, 0.778) 
∆GAHS 2.10 
(1.72, 2.57) 
0.688 
(0.649, 0.726) 
0.752* 
(0.663, 0.811) 
1.95 
(1.68, 2.27) 
0.678 
(0.639, 0.716) 
0.737* 
(0.694, 0.780) 
∆MELD 1.68 
(1.13, 1.21) 
0.714 
(0.675, 0.750) 
0.749* 
(0.692, 0.806) 
1.16 
(1.12, 1.19) 
0.678 
(0.639, 0.716) 
0.725* 
(0.682, 0.768) 
ABIC# 1.68 
(1.46, 1.94) 
0.695 
(0.658, 0.731) 
0.677 
(0.622, 0.732) 
1.66 
(1.49, 1.86) 
0.703 
(0.666, 0.739) 
0.673 
(0.632, 0.714) 
GAHS# 1.65 
(1.42, 1.94) 
0.698 
(0.661, 0.733) 
0.670 
(0.623, 0.729) 
1.58 
(1.41, 1.78) 
0.677 
(0.640, 0.714) 
0.654 
(0.615, 0.693) 
MELD# 1.12 
(1.08, 1.15) 
0.672 
(0.634, 0.708) 
0.658 
(0.603, 0.713) 
1.11 
(1.08, 1.14) 
0.668 
(0.630, 0.705) 
0.652 
(0.611, 0.693) 
95% Confidence Intervals in parentheses 
*adjusted relative to baseline values 
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Supplementary Table 2: 
A) Mortality in Patients with Low Static Scores  
 28-Day Outcome 90-Day Outcome 
Mortality Significance; 
95%CI 
Mortality Significance; 
95%CI 
MELD<25 Pred 6.3% P = 0.016 
0.305 to 0.869 
16.2% P = 0.492 
0.597, 1.282 Non-Pred 11.8% 17.8% 
ABIC<6.71 Pred 1.4% P = 0.115 
0.0424 to 1.041 
7.6% P = 0.939 
0.337, 3.242 Non-Pred 6.3% 8.2% 
GAHS<9 Pred 4.4% P = 0. 025 
0.247 to 0.881 
14.4% P = 0.660 
0.589, 1.399 Non-Pred 9.3% 15.4% 
 
B) Mortality in Patients with Consistently Low Static Scores 
 28-Day Outcome 90-Day Outcome 
Mortality Significance; 
95%CI 
Mortality Significance; 
95%CI 
MELD<25 Pred 5.7% P = 0.162 
0.353 to 1.185 
15.8% P = 0.740 
0.708, 1.626 Non-Pred 8.6% 14.4% 
ABIC<6.71 Pred 1.4% P = 0.108 
0.0413 to 1.014 
8.3% P = 0.976 
0.328, 3.155 Non-Pred 6.6% 7.9% 
GAHS<9 Pred 3.3% P = 0.175 
0.240 to 1.276 
11.8% P = 0.789 
0.634, 1.824 Non-Pred 5.9% 11.2% 
 
Pred: Prednisolone treatment; Non-Pred: Not treated with Prednisolone; 95%CI: 
95% Confidence Interval 
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Table 4: 
A) Mortality in all Patients with High Static Scores 
 28-Day Outcome 90-Day Outcome 
Mortality Significance; 
95%CI 
Mortality Significance; 
95%CI 
MELD≥25 Pred 24.8% P=0.330 
0.828 to 1.762 
42.2% P=0.71 
0.694 to 1.282 Non-Pred 29.1% 39.2% 
ABIC≥6.71 Pred 15.9% P=0.067 
0.980 to 1.829 
29.9% P=0.894 
0.796 to 1.298 Non-Pred 20.7% 29.3% 
GAHS≥9 Pred 24.2% P=0.180 
0.895 to 1.774 
40.2% P=0.960 
0.762 to 1.331 Non-Pred 28.8% 38.8% 
 
B) Mortality in Patients with High Static Scores (excluding patients presenting 
with GIB or Sepsis) 
 28-Day Outcome 90-Day Outcome 
Mortality Significance; 
95%CI 
Mortality Significance; 
95%CI 
MELD≥25 Pred 22.2% P = 0.130 
0.903, 2.150 
41.3% P = 0.970 
0.714, 1.418 Non-Pred 28.9% 39.6% 
ABIC≥6.71 Pred 14.6% P = 0.021 
1.063, 2.131 
29.6% P=0.698 
0.805, 1.383 Non-Pred 21.0% 29.4% 
GAHS≥9 Pred 21.0% P = 0.039 
1.022, 2.242 
38.5% P = 0.640 
0.785, 1.482 Non-Pred 29.3% 38.4% 
 
Pred: Prednisolone treatment; Non-Pred: Not treated with Prednisolone; 95%CI: 
95% Confidence Interval 
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Table 5: Effect of Prednisolone upon Day 7 bilirubin and Day 7 scores of Response. 
 
 %Change in 
Bilirubin 
(95%CI) 
Proportion with Favourable Day 7 Score 
Lille <0.45 %∆Bili ≥25% Change in 
‘static’ score* 
GAHS>8 No Prednisolone -1.6% 
(-6.4, 3.2) 
27.5% 20.8% 37.0% 
Prednisolone -17.5% 
(-22.4, -12.6) 
45.4% 43.3% 41.6% 
ABIC≥6.7 No Prednisolone -4.0% 
(-8.2, -0.2) 
40.4% 25.0% 42.5% 
Prednisolone -20.4% 
(-24.1, -16.7) 
55.4% 49.8% 68.8% 
MELD≥25 No Prednisolone -0.2% 
(-5.6, 5.2) 
29.1% 18.3% 34.8% 
Prednisolone -12.0% 
(-17.5, -6.6) 
48.7% 33.6% 59.2% 
*refers to change in relevant ‘static’ score 
Comparison of Prednisolone treated and untreated patients: 
Difference in percentage change in bilirubin: 
GAHS>8: p<0.0001 (95%CI 9.07, 22.81) 
ABIC>6.7: p=0.001 (95%CI 22.06, 10.79) 
MELD>25; p=0.0026 (95%CI 4.14, 19.5) 
All differences in proportions with a favourable Day 7 score significant (p<0.05) except the 
∆GAHS at Day-7 for GAHS>8. 
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Figure 2: Kaplan-Meier Survival Probability for Patients Stratified by ‘Static’ Scores 
(only high baseline scores treated with prednisolone) combined with ‘Dynamic’ 
Scores (excluding initial presentation with GIB or sepsis). R: Responder; NR: Non-
responder 
A) DF/Lille; B) MELD/Lille; C) ABIC/ Lille; D) GAHS/Lille; E) GAHS/∆GAHS 
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Table 6: Application of Scores to Different Therapeutic Strategies and 90-Day 
Mortality. Prednisolone treatment offered to those not presenting primarily with either 
Gastrointestinal bleeding or Sepsis initially. 
 
 Low ‘Static’ 
Score: 
No Prednisolone 
High ‘Static’ Score: 
Prednisolone Treated 
TOTAL 
CUMULATIVE 
90-DAY 
MORTALITY Mortality Proportion Responder 
Mortality 
Non-Responder 
Mortality 
DF/Lille - 100% 15.4% 43.5% 26.8%* 
MELD/Lille  
14.4% 
 
39.0% 
25.4% 55.2% 21.8% 
MELD/%∆Bili 26.3% 48.0% 21.8% 
MELD/∆MELD 24.6% 66.7% 21.6% 
ABIC/Lille  
7.9% 
 
85.7% 
15.3% 42.9% 23.7% 
ABIC/%∆Bili 17.1% 44.4% 23.8% 
ABIC/∆ABIC 19.1% 54.7% 24.2% 
GAHS/Lille  
11.2% 
 
47.0% 
23.1% 47.4% 20.6% 
GAHS/%∆Bili 18.5% 47.1% 20.3% 
GAHS/∆GAHS 11.5% 50.7% 19.2%* 
 
*Difference in mortality: p=0.026: 95%CI 0.63% to 14.72% 
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Supplementary Figure 2: Flowchart showing the Stratification of Patients with 
Alcoholic Hepatitis in the STOPAH Trial. 
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GRAPHIC ABSTRACT 
AUC for MELD, GAHS and ABIC Scores: MELD, ABIC and GAHS are superior to 
the DF in alcoholic hepatitis 
 
 
 
 
 
  
 AUC 
 28 Day 
Outcome 
Comparison with DF 90 Day 
Outcome 
Comparison with 
DF 
DF 0.673 - 0.670 - 
ABIC 0.747 p=0.008 
(0.020 to 0.128) 
0.726 p=0.02 
(0.009 to 0.103) 
GAHS 0.753 p=0.001 
(0.032 to 0.128) 
0.713 p=0.04 
(0.002 to 0.084) 
MELD 0.732 p=0.001 
(0.026 to 0.093) 
0.704 p=0.02 
(0.006 to 0.062) 
28 Day Outcome 
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HIGHLIGHTS 
 
• Newer ‘Static’ Scores (MELD, ABIC, GAHS) are superior to DF in Alcoholic 
Hepatitis 
• Consistently low ‘static’ scores have a favourable outcome not improved with 
prednisolone 
• Scores incorporating evolution of bilirubin or change of ‘static’ scores predict 
90-day outcome 
• Limiting treatment to high ‘static’ scores reduces exposure to prednisolone 
and improves outcome 
 
